MedTrace Logo

A Study Comparing Swallowed Flovent and Placebo in Patients With Eosinophilic Disorders

NCT00266578 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2013-04-11

No results posted yet for this study

Summary

The purpose of this study is assessing the efficacy of swallowed Flovent® vs. placebo for the treatment of eosinophilic esophagitis (EE).

Conditions

  • Eosinophilic Esophagitis

Interventions

DRUG

Fluticasone Propionate

Flovent vs. placebo daily for 3 months

Sponsors & Collaborators

  • Marc Rothenberg

    lead OTHER

Principal Investigators

  • Marc E. Rothenberg, M.D., Ph.D. · Children's Hospital Medical Center, Cincinnati

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
3 Years
Max Age
30 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-10-31
Primary Completion
2006-11-30
Completion
2012-10-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00266578 on ClinicalTrials.gov